Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study

Suhayl Dhib-Jalbut, Sumandeep Sumandeep, Reuben Valenzuela, Kouichi Ito, Payal Patel, Mark Rametta

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

We measured immune markers in subjects with multiple sclerosis (MS) treated with IFNβ-1b for 12. months. IL-17 levels were significantly higher at Month 6 (p=0.036) in relapsing subjects while BDNF levels were significantly higher at Month 3 (p=0.028) in relapse-free subjects. Change from baseline in IL-4 levels inversely correlated with disability score whereas change from baseline in IL-10/IFN-gamma ratio inversely correlated with occurrence of relapses. CXCR3 + CD8. + T-cells tended to be higher but declined with treatment in relapse-free compared with relapsing subjects. Findings show the potential of cytokine and neurotrophic factors as biomarkers of clinical response to IFNβ-1b.

Original languageEnglish (US)
Pages (from-to)131-140
Number of pages10
JournalJournal of Neuroimmunology
Volume254
Issue number1-2
DOIs
StatePublished - Jan 15 2013

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Keywords

  • Cytokines
  • Immune markers
  • Interferon beta-1b
  • Multiple sclerosis

Fingerprint Dive into the research topics of 'Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study'. Together they form a unique fingerprint.

Cite this